Two-Pronged attack tested for tough cancers

NCT ID NCT04779151

Summary

This study tested whether combining two drugs, niraparib and dostarlimab, could help control advanced cancers that had specific genetic problems or were previously sensitive to platinum chemotherapy. It involved 51 adults with various cancers, including bladder, stomach, and kidney cancer, who had already tried other treatments. The goal was to see if the drug combo could stop tumor growth and help the immune system fight the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Gustave Roussy

    Villejuif, Val de Marne, 94800, France

Conditions

Explore the condition pages connected to this study.